Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
文献类型：期刊论文
| 作者 | Chen, Hongjie6,7; Hu, Yangchan6,7; Zhuang, Zirui4,5,6; Wang, Dingyi6,7; Ye, Zu2,3; Jing, Ji2,6; Cheng, Xiangdong1,2,3 |
| 刊名 | CANCERS
 |
| 出版日期 | 2023-11-01 |
| 卷号 | 15期号:21页码:19 |
| 关键词 | gastric cancer DNA damage repair PARP inhibitor cancer therapy |
| DOI | 10.3390/cancers15215114 |
| 通讯作者 | Jing, Ji(jingji@him.cas.cn) ; Cheng, Xiangdong(chengxd@zjcc.org.cn) |
| 英文摘要 | Simple Summary Gastric cancer (GC) is a highly aggressive malignancy affecting the digestive system and characterized by notable variations in its nature. Although survival rates have observed some enhancements, the prognosis remains grim, and mortality rates remain high. There is an immediate demand for innovative treatment strategies. Recent investigations have identified frequent mutations in genes responsible for repairing DNA damage in GC patients, highlighting the potential of PARP inhibitors (PARPi) as a promising therapeutic option. This article offers a comprehensive examination of the progress and hurdles in the development of PARPi for treating GC.Abstract Gastric cancer (GC) is a common and aggressive cancer of the digestive system, exhibiting high aggressiveness and significant heterogeneity. Despite advancements in improving survival rates over the past few decades, GC continues to carry a worrisome prognosis and notable mortality. As a result, there is an urgent need for novel therapeutic approaches to address GC. Recent targeted sequencing studies have revealed frequent mutations in DNA damage repair (DDR) pathway genes in many GC patients. These mutations lead to an increased reliance on poly (adenosine diphosphate-ribose) polymerase (PARP) for DNA repair, making PARP inhibitors (PARPi) a promising treatment option for GC. This article presents a comprehensive overview of the rationale and development of PARPi, highlighting its progress and challenges in both preclinical and clinical research for treating GC. |
| WOS关键词 | UP-TO-DATE ; DNA-REPAIR ; HELICOBACTER-PYLORI ; RECOMBINATION REPAIR ; PHOTODYNAMIC THERAPY ; SYNTHETIC LETHALITY ; GERMLINE MUTATIONS ; POLY(ADP-RIBOSE) ; EXPRESSION ; DAMAGE |
| 资助项目 | We extend our gratitude to all researchers for their insightful investigations into PARP and PARPi within the context of gastric cancer. |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:001099449900001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307860]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Jing, Ji; Cheng, Xiangdong |
| 作者单位 | 1.Zhejiang Canc Hosp, Zhejiang Prov Res Ctr Upper Gastrointestinal Tract, Hangzhou 310022, Peoples R China 2.Zhejiang Key Lab Prevent Diag & Therapy Upper Gast, Hangzhou 310022, Peoples R China 3.Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Gastr Surg, Hangzhou 310022, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 5.Univ Chinese Acad Sci UCAS, Hangzhou Inst Adv Study, Sch Mol Med, Hangzhou 310024, Peoples R China 6.Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Hangzhou 310022, Peoples R China 7.Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Hongjie,Hu, Yangchan,Zhuang, Zirui,et al. Advancements and Obstacles of PARP Inhibitors in Gastric Cancer[J]. CANCERS,2023,15(21):19. |
| APA | Chen, Hongjie.,Hu, Yangchan.,Zhuang, Zirui.,Wang, Dingyi.,Ye, Zu.,...&Cheng, Xiangdong.(2023).Advancements and Obstacles of PARP Inhibitors in Gastric Cancer.CANCERS,15(21),19. |
| MLA | Chen, Hongjie,et al."Advancements and Obstacles of PARP Inhibitors in Gastric Cancer".CANCERS 15.21(2023):19. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。